ADCs : antibodies and cytotoxic molecules united against tumours
From Paul Ehrlich’s early “magic bullet” concept to today’s approved therapeutics, Antibody-Drug Conjugates (ADCs) represent a major breakthrough in targeted cancer therapy. By combining the selectivity of monoclonal antibodies with the potency of cytotoxic agents, ADCs aim to eliminate tumor cells while sparing healthy tissues. This article dives into the evolution, design strategies, and key challenges of these complex biologics.
Multiple Sclerosis
This month’s MabDesign market analysis gives you an overview of market dynamics and development projects targeting the treatment of multiple sclerosis.
Glioblastoma
This month’s MabDesign market analysis gives you an overview of market dynamics and pipeline projects targeting the glioblastoma.
Therapeutic vaccines in oncology
This month, MabDesign’s market analysis provides an overview of the market for therapeutic oncology vaccines.